Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
RATIONALE: Prior studies have shown an anticancer effect of metformin in patients with breast and colorectal cancer. It is unclear, however, whether metformin has a mortality benefit in lung cancer. OBJECTIVES: To compare overall survival of patients with diabetes with stage IV non-small cell lung cancer (NSCLC) taking metformin versus those not on metformin. METHODS: Using data from the Surveillance, Epidemiology, and End Results registry linked to Medicare claims, we identified 750 patients with diabetes 65-80 years of age diagnosed with stage IV NSCLC between 2007 and 2009. We used propensity score methods to assess the association of metformin use with overall survival while controlling for potential confounders. MEASUREMENTS AND MAIN RESULTS: Overall, 61% of patients were on metformin at the time of lung cancer diagnosis. Median survival in the metformin group was 5 months, compared with 3 months in patients not treated with metformin (P < 0.001). Propensity score analyses showed that metformin use was associated with a statistically significant improvement in survival (hazard ratio, 0.80; 95% confidence interval, 0.71-0.89), after controlling for sociodemographics, diabetes severity, other diabetes medications, cancer characteristics, and treatment. CONCLUSIONS: Metformin is associated with improved survival among patients with diabetes with stage IV NSCLC, suggesting a potential anticancer effect. Further research should evaluate plausible biologic mechanisms and test the effect of metformin in prospective clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 1×
“We used the Deyo adaptation of Charlson’s index to assess the burden of comorbidities (21-23) and data about use of home health services (restricted to homebound patients) as a proxy for poor performance status (24).”
MethodAMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115 · cited 1×
“Metformin may also act directly on tumor cells by altering intracellular signaling pathways leading to a decrease in cell proliferation (38-43).”
Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038 · cited 1×
“Patients with diabetes are at higher risk for developing cancer, including breast, colorectal, pancreatic and lung malignancies (6-9).”
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566 · cited 2×
“Metformin also appears to be associated with improved survival among diabetic patients with breast, prostate and colorectal cancer (14, 16, 17).”
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493 · cited 1×
“Among these medications being evaluated, metformin, a biguanide derivative commonly used to treat type II diabetes, has been found to have anti-cancer activity in preclinical models (4, 5).”
Molecular mechanism of action of metformin: old or new insights?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Diabetologia · doi:10.1007/s00125-013-2991-0 · Cited by 479
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428 · cited 1×
“9 There have been few publications examining metformin’s influence on lung cancer risk (31-34).”
Diabetes and cause-specific mortality in a prospective cohort of one million U.S. Adults
Campbell, P. T., Newton, C. C., Patel, A. V., Jacobs, E. J., & Gapstur, S. M. (2012) · Diabetes Care · doi:10.2337/dc12-0002 · Cited by 339 · cited 1×
“Patients with diabetes are at higher risk for developing cancer, including breast, colorectal, pancreatic and lung malignancies (6-9).”
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth
Algire, C., Zakikhani, M., Blouin, M.-J., Shuai, J. H., & Pollak, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0038 · Cited by 185
Cited by
Metformin: A Hopeful Promise in Aging Research
Novelle, M. G., Ali, A., Diéguez, C., Bernier, M., & de Cabo, R. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025932 · Cited by 178
“Chronic treatment with metformin among patients with diabetes might reduce the risk of cognitive decline and dementia (Ng et al. 2014; Patrone et al. 2014) and improve survival in several types of cancer (Greenhill 2015; Ko et al. 2015; Lin et al. 2015; Rego et al. 2015).”
BackgroundRociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1506831 · Cited by 61
Chuang, M.-C., Yang, Y.-H., Tsai, Y.-H., Hsieh, M.-J., Lin, Y.-C., Lin, C.-K., Chen, P.-C., & Yang, T.-M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191129 · Cited by 29
Shining a light on metabolic vulnerabilities in non-small cell lung cancer
Dowling, C. M., Zhang, H., Chonghaile, T. N., & Wong, K.-K. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188462 · Cited by 26
Xin, W.-X., Fang, L., Fang, Q.-L., Zheng, X.-W., Ding, H.-Y., & Huang, P. (2018) · Medicine · doi:10.1097/md.0000000000010035 · Cited by 18
“Insulin exposure and lung cancer outcomes Among the 18 selected studies, 2 studies carried by Lin et al([27]) and Tseng([24]) investigated the prognostic association between insulin exposure and OS of lung cancer patients.”
BackgroundInfluential
Metadata
- Authors
- Lin, J. J., Gallagher, E. J., Sigel, K., Mhango, G., Galsky, M. D., Smith, C. B., LeRoith, D., & Wisnivesky, J. P.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-02-15
- Volume
- 191
- Issue
- 4
- Pages
- 448-454
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2151151767
- Cited by
- 137
- References
- 12
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.